Rice Bran-based Supplemental Foods for the Treatment of Childhood Malnutrition
NCT ID: NCT05319717
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2022-12-01
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Acceptability of RUTFs in Indonesia
NCT05614505
Pilot Feasibility of Rice Bran Supplementation in Children
NCT02557373
Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia
NCT02257762
Ready to Use Supplementary Food in Moderate Childhood Malnutrition
NCT01147198
Nutritional Intervention For The Treatment Of Uncomplicated SAM
NCT05390437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will yield new information of direct importance and impact to public health nutrition and advance our knowledge and treatment of SAM in Indonesia. Investigation of the gut-microbiota metabolism following consumption of rice bran provided in RUTFs compared to RUTF without rice bran included will provide key mechanistic insights for repairing nutrient absorptive functions in the gut, sustaining gut health in treated children and inform long-term treatment solutions for SAM.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Intervention study arm: Locally produced Ready to use therapeutic food plus rice bran (RUTF+RB)
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ready-to-use therapeutic food, no rice bran (control/comparator)
Randomized participants will receive a locally produced ready-to-use therapeutic food to be consumed daily.
Ready-to-use therapeutic food (no rice bran)
Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
Ready-to-use therapeutic food, with heat stabilized rice bran (Experimental)
Randomized participants will receive a locally produced ready-to-use therapeutic food with 5% heat stabilized rice bran to be consumed daily.
Ready-to-use therapeutic food with heat stabilized rice bran
Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ready-to-use therapeutic food with heat stabilized rice bran
Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
Ready-to-use therapeutic food (no rice bran)
Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Child identified with a weight-for-height z-score WHZ of \< -2.5 (SAM children and children with advanced moderate acute malnutrition) and/or mid-upper arm circumference (MUAC) \<115 mm) or a child with mild to moderate nutritional edema (regardless of anthropometry).
* Being qualified for outpatient treatment.
* Aged 6-59 months old upon enrolment
* Pass appetite test (taste test) (as stipulated by WHO guidelines on the treatment of SAM). See appetite test document attached.
* Not having consumed RUTF in the last two months
Exclusion Criteria
* Children 6-59 months old who, when diagnosed with SAM, have been detected with medical complications, with TB, HIV positive status, one or more signs from the Integrated Management of Childhood Illness (IMCI) guidelines, severe oedema (+++) or who have failed the appetite test (see appetite test document attached).
* Medical complications include: Cough/difficulty in breathing; Diarrhea; Fever; Ear Problems. IMCI signs will be identified according to WHO definition and include not able to drink or breastfeed; vomiting; convulsions; lethargy.
* Participating in another clinical trial
* Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician).
* SAM with complications requiring hospital treatment. (Upon discharge from hospital, the child will be re-evaluated for inclusion in the study).
* Siblings will not be allowed to participate in the trial
Withdrawal criteria:
* Not consuming the RUTF supplementation at all in \>4 days a week in 2 consecutive weeks.
* Not providing samples or completing forms/questionnaires at study visits
* Developing medical complications requiring hospitalization
* Not gaining weight after 1 month of treatment
* Major reactions to intervention
6 Months
59 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thrasher Research Fund
OTHER
Savica, Indonesia
UNKNOWN
Institute of Research for Development, France
OTHER_GOV
Colorado State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elizabeth P Ryan
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Damayanti Soekarjo, PhD
Role: PRINCIPAL_INVESTIGATOR
Savica, Indonesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Savica
Jember, East Java, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Weber AM, Barbazza S, Fauzi MD, Rachmadewi A, Zuhrina R, Putri FK, Campos Ponce M, Hoeven MV, Rimbawan R, Nasution Z, Giriwono PE, Wieringa FT, Soekarjo DD, Ryan EP. Solutions to Enhance Health with Alternative Treatments (SEHAT) protocol: a double-blinded randomised controlled trial for gut microbiota-targeted treatment of severe acute malnutrition using rice bran in ready-to-use therapeutic foods in Indonesia. BMJ Open. 2023 Nov 24;13(11):e076805. doi: 10.1136/bmjopen-2023-076805.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSU IRB#:1823
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.